系统性硬化症中原发性醛固酮增多症标志物的评估及其与肾脏和心血管结局的关系
本研究为单中心研究,纳入112例成人系统性硬化症(SSc)患者和48例血压正常健康对照。基线时37%的SSc患者有高血压,末次随访时增至52%;基线ARR阳性者在SSc中占8%,在高血压亚组中占12%。未观察到PA标志物与SSc相关肾脏和心血管结局或末次随访时高血压存在关联。
要点
- SSc患者高血压常见,基线37%,末次随访增至52%。
- 高血压SSc患者中PA筛查试验阳性率估计为12%。
- PA标志物与SSc相关肾脏和心血管结局或末次随访高血压无关联。
核心结论
- SSc队列中高血压常见,高血压SSc患者中PA筛查试验阳性率估计为12%,支持考虑在此人群中进行PA筛查。
研究设计与样本
- 单中心研究,分析112例成人SSc患者和48例血压正常健康对照的数据。
- 高血压定义为两次就诊血压≥140/90 mm Hg或病历记录有高血压。
- 采用醛固酮与肾素比值(ARR)进行PA筛查,并使用多变量回归模型评估PA生物标志物与高血压及SSc相关结局的关联。
主要发现
- SSc患者中位(IQR)年龄60(49,69)岁,79%为女性;健康对照中位(IQR)年龄42.5(31,57)岁,52%为女性。
- 基线时41例SSc患者(37%)有高血压,末次随访时(中位随访5.1年)增至队列的52%。
- SSc中基线ARR阳性的患病率为8%(9/112),在高血压亚组中为12%(5/41)。
- 未观察到PA生物标志物与SSc相关肾脏和心血管结局或末次随访时高血压存在关联。
临床怎么用
- 在高血压SSc患者中可考虑进行PA筛查,因该亚组ARR阳性率估计为12%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether primary aldosteronism (PA), the most common endocrine cause of hypertension (HTN), contributes to HTN and cardiovascular disease burden in systemic sclerosis (SSc) has never been explored. We aimed to assess the prevalence and management of HTN, prevalence of positive PA screening test results and the associations between markers of PA with HTN and SSc-related outcomes in SSc. METHODS: Data from adult SSc patients and normotensive healthy controls (HC) were analysed in this single-centre study. HTN was defined as blood pressures ≥140/90 mm Hg on two visits or as documented in medical records. PA screening was performed using the aldosterone:renin ratio (ARR). Associations between biomarkers of PA (renin, aldosterone, ARR, hybrid steroid 18-hydroxycortisol (18OHF)) with HTN and SSc-related outcomes were assessed using multivariable regression modelling. RESULTS: Data from 112 SSc patients (median (IQR) age 60 (49, 69) years, 79% female) and 48 HC (median (IQR) age 42.5 (31, 57) years, 52% female) were analysed. At baseline, 41 SSc patients (37%) had HTN, increasing to 52% of the cohort at the last follow-up visit (median follow-up 5.1 years). The prevalence of positive baseline ARR in SSc was 8% (9/112), corresponding to 12% (5/41) in the hypertensive subset. No associations were observed between biomarkers of PA and SSc-related renal and cardiovascular outcomes or HTN at last follow-up visit. CONCLUSIONS: HTN was common in this SSc cohort, and prevalence of positive PA screening test was estimated at 12% among hypertensive SSc patients, supporting consideration of PA screening in this population.
引用
- Collet A, Sanges S, Espiard S, et al. Assessment of markers of primary aldosteronism in systemic sclerosis and their relationships with renal and cardiovascular outcomes. RMD Open. 2026. PMID: 42457209. doi:10.1136/rmdopen-2026-006930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。